The Russian government has dedicated approximately 600 million rubles from its reserve fund to acquire equipment for establishing a production facility focused on innovative drugs utilizing matrix ribonucleic acid (mRNA). These drugs can be used to treat cancer, among other things. The corresponding order was signed by the Chairman of the Russian Government Mikhail Mishustin.
The subsidy is allocated to the Gamaleya National Research Center for Epidemiology and Microbiology, which will facilitate the production of these vital drugs. It is expected that at least 41 units of equipment will be purchased with the allocated funds to launch the new production facility.
At a government meeting, Mikhail Mishustin noted that the new equipment will create the necessary infrastructure for the production of medicines, which is important for timely treatment of patients and reducing dependence on foreign supplies.
